Business Description
Neoleukin Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US03842B1017
Description
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.34 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | -0.33 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -6.8 | |||||
| 3-Year EPS without NRI Growth Rate | -9 | |||||
| 3-Year FCF Growth Rate | -12 | |||||
| 3-Year Book Growth Rate | -16 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.62 | |||||
| 9-Day RSI | 53.59 | |||||
| 14-Day RSI | 51.71 | |||||
| 6-1 Month Momentum % | -13.46 | |||||
| 12-1 Month Momentum % | 53.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.33 | |||||
| Quick Ratio | 15.33 | |||||
| Cash Ratio | 15.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | 14.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -39.28 | |||||
| ROA % | -32.66 | |||||
| ROIC % | -220.43 | |||||
| ROC (Joel Greenblatt) % | -276.96 | |||||
| ROCE % | -35.6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.1 | |||||
| Price-to-Tangible-Book | 0.1 | |||||
| EV-to-EBIT | 1.01 | |||||
| EV-to-EBITDA | 1.07 | |||||
| EV-to-FCF | 1.06 | |||||
| Price-to-Net-Current-Asset-Value | 0.12 | |||||
| Price-to-Net-Cash | 0.12 | |||||
| Earnings Yield (Greenblatt) % | 99.01 | |||||
| FCF Yield % | -401.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NLTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neoleukin Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -12.48 | ||
| Beta | 0 | ||
| Volatility % | 60.62 | ||
| 14-Day RSI | 51.71 | ||
| 14-Day ATR ($) | 0.899904 | ||
| 20-Day SMA ($) | 13.786 | ||
| 12-1 Month Momentum % | 53.88 | ||
| 52-Week Range ($) | 8.114 - 18.8 | ||
| Shares Outstanding (Mil) | 2.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neoleukin Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neoleukin Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neoleukin Therapeutics Inc Frequently Asked Questions
What is Neoleukin Therapeutics Inc(NLTX)'s stock price today?
The current price of NLTX is $3.49. The 52 week high of NLTX is $18.80 and 52 week low is $8.11.
When is next earnings date of Neoleukin Therapeutics Inc(NLTX)?
The next earnings date of Neoleukin Therapeutics Inc(NLTX) is 2024-05-08 Est..
Does Neoleukin Therapeutics Inc(NLTX) pay dividends? If so, how much?
Neoleukin Therapeutics Inc(NLTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers